CHICAGO, June 6, 2016 /PRNewswire/ — Polaris Group announced today that FLT-PET scan provided early evidence of response to arginine depletion by its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) in argininosuccinate synthetase (ASS1) deficient thoracic tumors.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2016-06-06 09:16:242018-02-19 09:20:32FLT-PET Scan Provides Early Evidence of Response to Arginine Depletion by ADI-PEG 20 in Argininosuccinate Synthetase Deficient Thoracic Tumors
CHICAGO, June 6, 2016 /PRNewswire/ — Polaris Group announced today that the phase III study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma (HCC) did not meet its primary endpoint of demonstrating overall survival (OS) benefits. Median OS was 7.8 months for ADI-PEG 20 vs. 7.4 months for placebo (p = 0.884, HR=1.022 [95% CI: 0.847, 1.233]).
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2016-06-03 18:00:222018-02-19 18:01:39ADI-PEG 20 plus Gemcitabine and nab-Paclitaxel Shows Robust Anti-tumor Activity in Advanced Pancreatic Cancer
SAN DIEGO, May 16, 2016 — Polaris Group announced today that it has received notification that the United States Patent and Trademark Office will issue to Polaris Group a new utility patent that will contain claims protecting the pharmaceutical composition of ADI-PEG 20 which Polaris Group plans to commercialize upon receiving regulatory approval, as well as claims covering therapeutic use of the compositions of ADI-PEG 20 for the treatment of a variety of cancer indications.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2016-05-16 18:02:362018-02-19 18:04:30Polaris Group Announces Issuance of New Patent Protecting Lead Product Candidate ADI-PEG 20
SAN DIEGO, May 5, 2016 – Polaris Group announced results from an ongoing phase 1 study that combines its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) with the standard first-line chemotherapy (cisplatin + pemetrexed doublet) in malignant pleural mesothelioma (MPM) demonstrating promising response rates.
Taipei, February 15, 2016 – Polaris Group announced today that its shares have been listed for trading on the Emerging Stock Board (ESB) of the Taipei Exchange (TPEx).
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2016-02-15 18:06:262018-02-19 18:08:26Polaris Group Shares Listed on the Emerging Stock Board of the Taipei Exchange
SAN DIEGO, January 22, 2016 – Polaris Group announced today that its wholly owned subsidiary DesigneRx Pharmeceuticals (DRX) (Chengdu) has completed the building constructions of its GMP manufacturing facility for biological drugs in Chengdu, China.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2016-01-22 18:09:162018-02-19 18:11:00Polaris Group Completes Construction of Its GMP Manufacturing Facility in China
VACAVILLE, CALIFORNIA, January 5, 2016 – Polaris Group today announced that its subsidiary DesigneRx Pharmaceuticals, Inc. (DRX) has completed construction of its new, expanded cGMP facility for manufacturing biological pharmaceuticals in Vacaville, California.
Taipei, October 12, 2015 – Polaris Group announced today that it has acquired ownership of all outstanding shares of TDW Group in a share exchange transaction. Prior to the acquisition, Polaris Group owned a 27% stake in TDW Group and following the acquisition, TDW Group became a wholly-owned subsidiary of Polaris Group.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2015-10-12 18:15:342018-02-19 18:17:04Polaris Group Acquires 100% Ownership of TDW Group
SAN DIEGO, June 25, 2015 – Polaris Group announced today that its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) was shown to have activity against primary acute myeloid leukemia (AML), both in vitro and in vivo, as reported in a research article published in the journal Blood.
SAN DIEGO, May 22, 2015 – Polaris Group announced today that it has filed a protocol amendment with the FDA to include two additional dose expansion cohorts treating uveal melanoma and glioblastoma in its ongoing phase 1 study that tests its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) in combination treatment with the standard first-line chemotherapy (cisplatin + pemetrexed doublet) in malignant plural mesothelioma (MPM) and non-squamous non-small cell lung carcinoma (NSCLC).
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x85.pngEmmy2015-05-22 18:19:142018-02-19 18:20:20Additional Tumor Type Cohorts Added to the Ongoing Phase 1 Study Combining ADI-PEG 20 with Cisplatin and Pemetrexed Based on New Research Results
FLT-PET Scan Provides Early Evidence of Response to Arginine Depletion by ADI-PEG 20 in Argininosuccinate Synthetase Deficient Thoracic Tumors
NewsCHICAGO, June 6, 2016 /PRNewswire/ — Polaris Group announced today that FLT-PET scan provided early evidence of response to arginine depletion by its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) in argininosuccinate synthetase (ASS1) deficient thoracic tumors.
ADI-PEG 20 plus Gemcitabine and nab-Paclitaxel Shows Robust Anti-tumor Activity in Advanced Pancreatic Cancer
NewsCHICAGO, June 6, 2016 /PRNewswire/ — Polaris Group announced today that the phase III study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma (HCC) did not meet its primary endpoint of demonstrating overall survival (OS) benefits. Median OS was 7.8 months for ADI-PEG 20 vs. 7.4 months for placebo (p = 0.884, HR=1.022 [95% CI: 0.847, 1.233]).
Polaris Group Announces Issuance of New Patent Protecting Lead Product Candidate ADI-PEG 20
NewsSAN DIEGO, May 16, 2016 — Polaris Group announced today that it has received notification that the United States Patent and Trademark Office will issue to Polaris Group a new utility patent that will contain claims protecting the pharmaceutical composition of ADI-PEG 20 which Polaris Group plans to commercialize upon receiving regulatory approval, as well as claims covering therapeutic use of the compositions of ADI-PEG 20 for the treatment of a variety of cancer indications.
Polaris Group’s ADI-PEG 20 Shows Robust Clinical Activity in Malignant Plural Mesothelioma When Combined with Standard First-Line Chemotherapy Regimen
NewsSAN DIEGO, May 5, 2016 – Polaris Group announced results from an ongoing phase 1 study that combines its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) with the standard first-line chemotherapy (cisplatin + pemetrexed doublet) in malignant pleural mesothelioma (MPM) demonstrating promising response rates.
Polaris Group Shares Listed on the Emerging Stock Board of the Taipei Exchange
NewsTaipei, February 15, 2016 – Polaris Group announced today that its shares have been listed for trading on the Emerging Stock Board (ESB) of the Taipei Exchange (TPEx).
Polaris Group Completes Construction of Its GMP Manufacturing Facility in China
NewsSAN DIEGO, January 22, 2016 – Polaris Group announced today that its wholly owned subsidiary DesigneRx Pharmeceuticals (DRX) (Chengdu) has completed the building constructions of its GMP manufacturing facility for biological drugs in Chengdu, China.
Polaris Group Subsidiary Announces Expansion of cGMP Manufacturing Facility
NewsVACAVILLE, CALIFORNIA, January 5, 2016 – Polaris Group today announced that its subsidiary DesigneRx Pharmaceuticals, Inc. (DRX) has completed construction of its new, expanded cGMP facility for manufacturing biological pharmaceuticals in Vacaville, California.
Polaris Group Acquires 100% Ownership of TDW Group
NewsTaipei, October 12, 2015 – Polaris Group announced today that it has acquired ownership of all outstanding shares of TDW Group in a share exchange transaction. Prior to the acquisition, Polaris Group owned a 27% stake in TDW Group and following the acquisition, TDW Group became a wholly-owned subsidiary of Polaris Group.
Polaris Group’s Lead Therapeutic ADI-PEG 20 Shows Activity against Primary Acute Myeloid Leukemia
NewsSAN DIEGO, June 25, 2015 – Polaris Group announced today that its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) was shown to have activity against primary acute myeloid leukemia (AML), both in vitro and in vivo, as reported in a research article published in the journal Blood.
Additional Tumor Type Cohorts Added to the Ongoing Phase 1 Study Combining ADI-PEG 20 with Cisplatin and Pemetrexed Based on New Research Results
NewsSAN DIEGO, May 22, 2015 – Polaris Group announced today that it has filed a protocol amendment with the FDA to include two additional dose expansion cohorts treating uveal melanoma and glioblastoma in its ongoing phase 1 study that tests its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) in combination treatment with the standard first-line chemotherapy (cisplatin + pemetrexed doublet) in malignant plural mesothelioma (MPM) and non-squamous non-small cell lung carcinoma (NSCLC).